Pragma

Pragma Bio is a biotechnology company leveraging a genome-to-phenome platform to discover novel medicines from the human microbiome. By mapping the "dark matter" of the microbiome—the vast array of uncharacterized microbes and their metabolites—the company identifies bioactive molecules with therapeutic potential in oncology and immunology. Pragma Bio utilizes advanced machine learning and synthetic biology to accelerate the transition from genomic data to validated drug candidates. Their approach focuses on identifying how microbial signals modulate the human immune system to treat complex diseases. The company's platform integrates multi-omics data to uncover functional relationships between microbial genes and human health outcomes.